← Eichor
Condition: Relapsed Refractory Systemic Sclerosis Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Relapsed Refractory Systemic Sclerosis

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

A Study of OL-108 in Relapsed/Refractory Autoimmune Diseases
Phase 1 · 2 location(s) · Beijing GoBroad Hospital · NCT06980597Exploratory Clinical Study on the Safety and Efficacy of Anti- CD19/BCMA U CAR-T Cell Injection for the Treatment of Rel
EARLY_Phase 1 · 1 location(s) · Changhai Hospital · NCT07246096CAR T-cell Therapy Targeting CD19 and BCMA(QT-019C) in Patients With Relapse/Refractory Autoimmune Diseases
Phase 1 · 1 location(s) · Institute of Hematology & Blood Diseases Hospital, China · NCT07315087A Clinical Study of YTS109 Cell for R/R Autoimmune Diseases
Phase 1 · 1 location(s) · China Immunotech (Beijing) Biotechnology Co., Ltd. · NCT07104721A Clinical Study of YTS109 Cell in R/R Autoimmune Diseases
Phase 1 · 1 location(s) · China Immunotech (Beijing) Biotechnology Co., Ltd. · NCT06978647CAR T-cell Therapy Targeting CD19 and BCMA in Patients With Relapse/Refractory Autoimmune Diseases
Phase 1 · 1 location(s) · Institute of Hematology & Blood Diseases Hospital, China · NCT06941129Anti-CD19 IL-10/IL15 CAR-NK Cells in Refractory/Relapsed Autoimmune Diseases
NA · 1 location(s) · Second Affiliated Hospital, School of Medicine, Zhejiang Uni · NCT06614270Exploratory Clinical Study on YTS109 Cell Therapy for Autoimmune Diseases
Phase 1 · 2 location(s) · China Immunotech (Beijing) Biotechnology Co., Ltd. · NCT07236801AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Stud
Phase 2 · 52 location(s) · Artiva Biotherapeutics, Inc. · NCT06991114A Study of CC312 for Relapsed/Refractory Autoimmune Diseases
EARLY_Phase 1 · 1 location(s) · CytoCares Inc · NCT07193810Fourth-gen CAR T Cells Targeting BCMA/CD19 for Refractory Systemic Lupus Erythematosus (SLE)
Phase 1/Phase 2 · 1 location(s) · Essen Biotech · NCT06350110A Study of OL-CD19-GDT in Relapsed/ Refractory Autoimmune Diseases
Phase 1 · 1 location(s) · Beijing GoBroad Hospital · NCT07167537Autologous CD19/BCMA Dual-Target CAR-T for Relapsed/Refractory Autoimmune Diseases
Phase 1 · 1 location(s) · Beijing Boren Hospital · NCT07361094A Clinical Study of TI-0032-III Injection in Patients With Relapsed and Refractory Autoimmune Diseases
Phase 1 · 1 location(s) · Therorna · NCT07413341
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.